Positive full results from the Phase III TULIP-SC trial showed the subcutaneous (SC) administration of Saphnelo (anifrolumab) demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback